14.70
+0.10
+(0.68%)
At close: January 10 at 9:11:35 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-4,717.10
-4,528.20
-5,202.90
-4,866.30
-6,884.90
Investing Cash Flow
-102.10
-128.50
-207.50
-918.80
-3,963.50
Financing Cash Flow
-347.30
-929.70
7,783.60
2,380.20
8,005.60
Other Cash Adjustment Inside Change in Cash
--
--
--
--
30.20
End Cash Position
1,855.90
2,588.80
8,175.40
5,802.10
9,206.90
Capital Expenditure
--
-128.50
-227.60
-918.80
-3,963.50
Issuance of Capital Stock
--
--
--
304.10
306.00
Issuance of Debt
--
620.00
8,000.00
2,400.00
8,000.00
Repayment of Debt
--
-1,542.40
-200.00
-300.00
-210.00
Free Cash Flow
-4,845.60
-4,656.70
-5,430.50
-5,785.10
-10,848.40
12/31/2020 - 2/1/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NRXBF NUREXONE BIOLOGIC INC
0.4550
0.00%
FYB.F Formycon AG
62.50
+1.63%
VVY.AS Vivoryon Therapeutics N.V.
1.9900
-1.49%
FYB.DE Formycon AG
62.70
+1.46%
NRX.V NurExone Biologic Inc.
0.6800
+4.62%
NRSN NeuroSense Therapeutics Ltd.
1.0400
-6.31%
TRVN Trevena, Inc.
1.8200
-2.67%
PLRZ Polyrizon Ltd.
1.4700
-4.55%
CMND Clearmind Medicine Inc.
1.5300
+6.25%
GDTC CytoMed Therapeutics Limited
2.7600
+20.52%